跳至主要内容
临床试验/NL-OMON37989
NL-OMON37989已完成2 期

A prospective *proof of concept study* to evaluate the potential efficacy of ustekinumab in patients with moderate to severe hidradenitis suppurativa (acne ectopica) - HiTS (Hidradenitis suppurativa Treatment with Stelara)

niversitair Medisch Centrum Groningen0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Patient above 18 to 65 years old
  • Patient with hidradenitis suppurativa Hurley stage II-III
  • Failure on conventional therapy with topical and oral antibiotics or immunosuppresiva or surgical intervention or on previous TNF alpha therapy (is not obligatory)
  • Patient has to be able to fill in a dutch formulated questionnaire
  • Signed informed consent
  • Women of childbaring age should use contraception

排除标准

  • Patients unable to fill in the questionnaires (mentally or physically)
  • Pregnancy or breast feeding patients
  • Patients with an active (chronic) infection, e.g. hepatitis B or C, HIV, tuberculosis
  • History of malignancy in past 10 years, except a basal cell carcinoma
  • Patients with demyelinating disease
  • Heartfailure NYHA class III-IV
  • Patients with a known allergy/hypersensitivity reaction to ustekinumab or one of the preservatives
  • Vaccination with living virus/bacterium < 3 months before starting ustekinumab
  • Severe liver or kidney dysfunction > 1.5 times of the maximum allowable value

研究者

相似试验